Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
Abstract: Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumorspecific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, f...
Main Authors: | John Kouvaris, Haralabos Zabatis, Georgios A. Zacharias, Michael J. Koukourakis, Vassilios Kouloulias, Georgios V. Koukourakis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2008-08-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/13/8/1897/ |
Similar Items
-
Capecitabine and stereotactic radiation in the management of breast cancer brain metastases
by: Matthew N. Mills, et al.
Published: (2021-05-01) -
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
by: Jianjun Peng, et al.
Published: (2018-05-01) -
Comparison of Efficacy Between S-1 and Capecitabine/Fluorouracil on Advanced Colorectal Cancer: A Meta-analysis
by: ZHAO Rongchang, et al.
Published: (2019-12-01) -
Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
by: Lakshmi Chintala, et al.
Published: (2011-06-01) -
Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer
by: CHENG Jianping, et al.
Published: (2020-07-01)